Libya has received shipments of advanced cancer treatments for the first time, marking a significant step forward in improving oncology care and expanding access to modern treatment options for patients.
The National Cancer Control Authority confirmed the arrival of the drug Enhertu (100 mg), developed by AstraZeneca. The treatment is considered one of the most advanced globally, offering promising outcomes for patients with certain types of cancer.
In addition, the authority announced the receipt of Venclexta (100 mg), produced by AbbVie, further strengthening the country’s ability to treat complex oncology cases.
Officials described the move as a “qualitative leap” in Libya’s healthcare sector, as it introduces therapies that were previously unavailable in the country. The new treatments are expected to provide improved survival rates and better disease management for cancer patients.
The move comes as part of broader efforts by Libyan health authorities to upgrade medical services, reduce the need for treatment abroad, and ease the burden on patients and their families.
The National Cancer Control Authority said it will continue working to secure access to cutting-edge therapies, improve treatment protocols, and enhance the overall quality of care.
This development reflects a growing focus on modernising Libya’s healthcare system despite ongoing challenges, with increased attention on specialised care such as oncology.
